Drug Details
| General Information of the Drug (ID: DR1442) | ||||
|---|---|---|---|---|
| Name |
Growth factor
|
|||
| Molecular Type |
Protein
|
|||
| Disease | Diminished ovarian reserve [ICD-11: 5A80] | Phase 3 | [1] | |
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Citicoline | Escherichia coli | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Experimental
Result(s) |
Synergistic effects of a low-dose combination of the growth factor bFGF and citicoline after temporary experimental focal cerebral ischemia and furthermore support the effectiveness of a combination treatment regimen for the management of acute stroke. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | DNA topoisomerase II alpha (TOP2A) | Molecule Info | [3] | |
| DNA topoisomerase II beta (TOP2B) | Molecule Info | [3] | ||
| NetPath Pathway | TCR Signaling Pathway | Click to Show/Hide | ||
| 2 | IL4 Signaling Pathway | |||
| Panther Pathway | DNA replication | Click to Show/Hide | ||
| Pathway Interaction Database | Validated transcriptional targets of deltaNp63 isoforms | Click to Show/Hide | ||
| Reactome | G0 and Early G1 | Click to Show/Hide | ||
| WikiPathways | Retinoblastoma (RB) in Cancer | Click to Show/Hide | ||
| 2 | Integrated Pancreatic Cancer Pathway | |||
| 3 | Gastric cancer network 2 | |||
| 4 | Gastric Cancer Network 1 | |||
| 5 | Mitotic G1-G1/S phases | |||
